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Abstract
Randomised evaluations of surgical interventions are rare; some interventions have been widely
adopted without rigorous evaluation. Unlike other medical areas, the randomised controlled trial
(RCT) design has not become the default study design for the evaluation of surgical interventions.
Surgical trials are difficult to successfully undertake and pose particular practical and
methodological challenges. However, RCTs have played a role in the assessment of surgical
innovations and there is scope and need for greater use. This article will consider the design,
conduct and analysis of an RCT of a surgical intervention. The issues will be reviewed under three
headings: the timing of the evaluation, defining the research question and trial design issues.
Recommendations on the conduct of future surgical RCTs are made. Collaboration between
research and surgical communities is needed to address the distinct issues raised by the assessment
of surgical interventions and enable the conduct of appropriate and well-designed trials.
Background
The promotion of randomised controlled trials (RCTs) to
evaluate surgical interventions was once colourfully sug-
gested to be the 'fifth horseman of an apocalyptical surgi-
cal fundamentalism' [1]. While the value of the RCT
design has been more readily accepted by others, it has
not become the default study design for the evaluation of
new surgical interventions [2-4]. This article will consider
the challenges to successfully conducting an RCT evalua-
tion of a surgical intervention. Surgical interventions can
be defined as those which involve physically changing
body tissues and organs through manual operation such
as cutting, abrading, suturing or the use of lasers. It should
be noted that some authors use a wider definition of sur-
gical trials [3] which includes trials in a surgical context,
where surgery is involved but is not one of the interven-
tions under evaluation, for example a placebo-controlled
trial of ibuprofen for pain and disability relief after hip
replacement surgery [5]. While many of the issues raised
below have relevance for such trials, they have been much
more readily conducted and do not face the same chal-
lenges.
Since the epochal streptomycin trial in the 1940s, the RCT
design has been applied widely [6]. As understanding of
the nature of study design and of the influence of bias has
grown, the RCT design has for many become the 'gold
standard' of evaluation, the standard against which others
are compared. Through random allocation of partici-
pants, equally distributed groups are formed in a RCT.
This allows for any difference between treatment groups
to be confidently inferred to be due to the treatments
themselves and not any other factor, known or unknown
to be related to outcome. Where equipoise exists, it can be
argued from an ethical point of view that every participant
is guaranteed a (random) chance of receiving the best
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such as the Food and Drug Administration in the USA, the
RCT has been not only expected but mandated in the
pharmaceutical area. Through the strong promotion of
Chalmers amongst others [7] and the evidence-based
medicine movement in general, it is common for new
interventions to be evaluated in an RCT context. While
recognising RCTs as the 'gold standard', it has been sug-
gested that the design has a more limited role in assessing
surgery than for drug interventions [2,8,9]. However, find-
ings from alternative (non-randomised) study designs
cannot be given the same confidence, due to the substan-
tial risk of the introduction of bias. Comparisons of ran-
domised and non-randomised studies have shown that
the results can be divergent, in direction as well as magni-
tude [10]. While many surgeons accept the need in princi-
ple for RCTs, they struggle to reconcile their personal
involvement with their surgical experience.
Randomised comparisons of surgical interventions have
been performed for many years [7]. A number of surgical
interventions have been shown to be ineffective and later
discarded, in some cases following randomised compari-
sons [11]. Internal mammary artery ligation was a popu-
lar surgical procedure until two small RCTs, some 20 years
after the intervention was proposed, reported no benefit
over placebo surgery. There is, however, some evidence
that the growth in the number of RCTs being conducted
in surgery has stagnated and fallen behind other clinical
areas [8,12]. A review of one surgical journal found an
increase in the number of RCTs from 1990 to 2000 [13].
However, only 3.4% of all articles in leading surgical jour-
nals were RCTs [14]. Furthermore, of the RCTs published
in these journals during a ten-year period, less than one
half of the RCTs were a randomised comparison of a sur-
gical intervention against an alternative. The contrast with
other areas can be seen by comparing audits of the evi-
dence base for clinical practice in internal medicine and
several surgical specialties. Whereas one half of interven-
tions in internal medicine were judged to be based upon
evidence from RCTs, two surgery audits reported a quarter
or less [15-17].
While there are genuine challenges to conducting surgical
trials, concerns about the quality of surgical trials are often
more general and more readily addressable. Reviews of
urological and orthopaedic trauma trials, which recog-
nised the difficulties inherent in conducting surgical trials,
found poor compliance with the consort statement for
reporting RCTs, echoing the findings of an earlier review,
and may reflect generally poorer trial methodology [18-
20]. A lack of understanding about RCTs in surgical com-
munities and the need for better epidemiological and sta-
tistical training of surgeons have been noted [3,21].
Historical and ethos-related reasons as to why the surgical
community has been slow to change have been suggested
[4].
The difficulties of conducting an RCT of a surgical inter-
vention have long been recognised [21-25]. Surgical RCTs
may have suffered as understanding of bias has grown, as
the maximum safeguards against bias are difficult to
achieve, particularly compared with pure pharmaceutical
treatments. A review of surgical operative questions in the
gastrointestinal specialty suggested that while there was,
at least in principle, substantially more scope for RCTs,
there were many questions where an RCT was judged not
to be feasible [26]. A number of barriers to conducting
surgical RCTs have been suggested [2,3,9,27,28]. Stirrat
and colleagues produced a helpful summary of the issues
involved and some suggestions to overcome them [9].
More recently, two other groups have done similarly
[3,28]. An overview of the issues and possible solutions
will be reviewed under three headings: the timing of the
evaluation, defining the research question and trial design
issues. It should be noted that a systematic review and cor-
responding meta-analysis can play an invaluable role in
trial design.
Broadly, surgical trials can be classified into three generic
types: exploratory, explanatory and pragmatic trials.
Exploratory trials allow early assessment of new interven-
tions. An explanatory trial seeks to assess whether the
intervention can work under favourable conditions. In
contrast, a pragmatic trial seeks to inform clinical decision
making by evaluating an intervention in a realistic clinical
setting. General characteristics of the three types are
shown in Table 1, though in practice a trial may have
some characteristics that reflect more than one type or
which defy easy categorisation. In particular, a continuum
between explanatory and pragmatic trials exists [29]. It
should be noted that the evaluation of surgery, by its com-
plex nature, naturally fits a more pragmatic framework. By
adopting a generally pragmatic approach, the impact of
many of the trial design issues is diluted. For example,
legitimate variations in surgical/centre practice or some
patients not receiving surgery as initially planned can be
incorporated into the evaluation, as opposed to attempt-
ing to preclude them from occurring. Such an approach
evaluates a realistic management strategy involving the
surgical intervention. As a consequence, the findings from
a trial with this approach will be more widely applicable.
The timing of the evaluation
When to assess?
Unlike the four phases of clinical trials which map out the
evaluation of pharmaceutical interventions, the evalua-
tion of surgical interventions has been sporadic, with the
timing or existence of a randomised evaluation uncertain.
The absence of a strong regulatory framework has resultedPage 2 of 9
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limited and weak scientific evidence [3,30,31]. The classic
example of recent times has been the case of laparoscopic
cholecystectomy, where adoption was rapid, uncontrolled
and haphazard. RCT evaluation occurred late, after much
of the surgical community had already become convinced
of the worth of the technique [3,31]. Little, if any, ran-
domised evidence is usually available upon which to base
recommendations on safety and efficacy for new interven-
tional (including surgical) interventions [32]. Most surgi-
cal RCTs, as was the case for laparoscopic
cholecystectomy, are akin to phase III pharmaceutical tri-
als.
However, there is a role for early and appropriate RCTs to
allow rigorous and timely assessment. Indeed, in Chalm-
ers' seminal work on randomisation from the first patient,
he used a surgical example where randomisation from the
first handful of cases was undertaken [7]. Chalmers
argued strongly for early RCT assessment of surgical inno-
vations, arguing from ethical reasoning of guaranteeing a
patient's right to a (random) chance of receiving the best
treatment and also from the difficulty of fully informing
patients in the early cases of development [22]. Others
argue the need for a non-randomised study in a develop-
mental phase due to procedural refinement and associ-
ated learning effects [2,3]. However, the complementary
value of an early and later randomised comparison has
been highlighted [33]. An early evaluation could take the
form of an exploratory trial. Tracker trials have been pro-
posed as a flexible framework which encompasses the dif-
ferent stages of evaluating a new intervention in a single
study. Under such an approach, randomisation can take
place early, with procedural refinements and new inter-
vention options incorporated into the study by allowing
changes in the randomisation strategy. These develop-
ments are 'tracked' and assessed in subsequent statistical
analyses [34]. Once the technology and treatment options
have stabilised, a conventional phase III RCT could be
mounted within this framework as a continuation of the
tracker trial. The UK Endovascular Aneurysm Repair trials
adopted some features of this concept [28]. Despite the
scientific merits of such a comprehensive approach, to
date no fully fledged tracker trials have been undertaken.
The difficult balancing act of waiting until development
has settled, where early results can lead to the loss of equi-
poise, has long been recognised [7]. The challenge has
been distilled into what has become known as Buxton's
law: 'It is always too early [for rigorous evaluation] until
suddenly it's too late' [35]. Large surgical trials, once
major technology has stabilised, have become more com-
mon where equipoise still exists. Such trials will be
dependent on the persistence of equipoise (patient and
surgeon) and may fail to recruit as hoped [2]. Commercial
influences can come into play. In general, early and rigor-
ous randomised evaluation would seem to be the excep-
tion rather than the rule.
Funding
An important driver of the timing of an evaluation has
been availability of funding. Anecdotally it has been sug-
gested that surgical trials are often unfairly compared with
the expectation of a drug trial, and if a 'double-blind' pla-
cebo-controlled study is the standard to which it is held,
then a surgical trial will often be considered inferior. In
contrast to pharmaceutical treatments, there is generally
little commercial incentive for a company to fund ran-
domised surgical trials. The need for national funding
bodies to cater for surgical trials and explicitly recognise
the challenges has been noted [3]. A review of applica-
tions to the National Institutes of Health in the USA
showed that though surgical applications had grown over
the last 20 years it was at a lower rate than the overall
increase. The surgical success rate was also slightly lower
[36]. Infrastructure funding to support clinical trials units
Table 1: Characteristics of three generic forms of surgical trials
Study characteristic Exploratory trial Explanatory trial Pragmatic trial
Aim of evaluation To explore the impact of the 
intervention
To assess whether the intervention is 
efficacious
To assess whether the intervention is 
effective
Patient population Initially those presumed to be most 
likely to benefit, though later 
modification is allowed
Narrow inclusion criteria of patients 
expected to be most suited to 
treatment
Broad inclusion criteria reflecting 
variations in clinical practice between 
centres
Surgical setting Surgeon(s) with substantial generic 
surgical expertise
Surgeon(s) with expertise in the 
intervention under evaluation
Surgeons from multiple centres 
representing different levels of 
expertise
Intervention definition Freedom to develop and refine Tight definition and strictly 
controlled
Broader definition incorporating 
variations which reflect clinical 
practice
Outcomes of main focus Surgical process and short-term clinical 
outcomes
Short-term (sometimes surrogate) 
clinical outcomes
Longer-term clinical and patient-
reported outcomes 
(such as quality of life measures)Page 3 of 9
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increase capacity. While sufficient funding for rigorous
randomised evaluation of every surgical innovation may
not be realistic [4], major innovations should be subject
to rigorous evaluation and appropriate funding is needed.
Defining the Research Question
Choice of comparator
In defining the research question, the most important
decision is the choice of comparator. Sometimes surgical
intervention may be the only curative treatment. Compar-
ison of surgery against no active treatment or watchful
waiting may be appropriate where the condition is not
acute. The possibility of using placebo surgery will be con-
sidered later. A key consideration will be the ability to
recruit; this has been noted as being difficult, particularly
for medical versus surgical comparisons [9,37,38]. A
number of variations in randomisation strategies have
been adopted to combat the difficulty in recruiting sur-
geons and participants. Traditionally, a randomised trial
will involve the randomisation between two treatments
whereby the randomised treatment will be administered
by the same clinician. Where the treatments are from dif-
ferent clinical specialties, such as medical versus surgical
trials, this will not be case. However, where two surgical
treatments are being compared, it has been common for
both interventions to be performed by participating sur-
geons. If the difference between interventions is minor,
this may not be difficult to achieve. However, where dif-
ferences are more pronounced this can be problematic, as
surgeons may routinely only perform one or the other
intervention. Additionally, while the surgical community
can be in equipoise, individual surgeons may have strong
preferences. In light of these concerns, the use of expertise-
based randomised trials has been proposed as an alterna-
tive design, where participants are randomised to sur-
geons with expertise in the allocated intervention [25,39].
While some surgeons may perform both interventions,
there is no requirement to do so. Where expertise for both
surgical interventions is available in a centre, this would
seem a convenient solution. However, in a multicentre
trial, if some centres only have expertise in one interven-
tion, centre differences could lead to bias. More generally,
an expertise-based trial may not necessarily produce a
result generalisable to the whole surgical community, due
to the make up of the participating surgeons and centres.
Patient preferences are likely to be prominent when the
treatments differ greatly, for example in medical versus
surgical trials. Conducting parallel preference arms along-
side the randomised arms, often called the comprehensive
cohort design, allows collection of data from participants
who are unwilling to be randomised and addresses con-
cerns about generalisability due to low inclusion rates
[40]. However, the cost and limited added benefit has
resulted in limited usage. Offering a new intervention
only within the context of an RCT may lift participation
rates, though evidence for this is limited and this will only
be possible if widespread adoption has not occurred [41].
The randomisation by consent design (Zelen's design) has
been proposed to address the difficulty of gaining
informed consent [42]. Under this approach, eligible
patients are randomised and consent is sought post-ran-
domisation only for those receiving the new interven-
tions, with consent to standard care presumed
unnecessary. However, most agree this is not ethical and
only moves the problems downstream [28]. Insights into
the consenting process may enable increased participa-
tion while maintaining informed choice [43].
Where three or more treatment options are under evalua-
tion, along with the option of randomisation between all
treatments additional options which involve randomisa-
tion between subsets of interventions can be offered. In
principle this will allow surgeons who feel unable to ran-
domise between all treatments to participate in a stratum
with which they feel comfortable. For example, the STARS
trial involved an evaluation of three surgical interven-
tions: reduction and fixation, bipolar hemiarthroplasty
and total arthroplasty [44]. Participating surgeons were
offered two choices: to randomise between all three inter-
ventions, or only between reduction and fixation, and
hemiarthroplasty. As noted by Lilford and colleagues, evi-
dence from non-randomised (indirect) comparisons may
account for centre differences [28].
Intervention definition and inclusion criteria
Trials which evaluate a surgical intervention will come
under scrutiny regarding the patient population and the
integrity of the treatment groups [3,21]. A surgical inter-
vention can be viewed as a complex intervention [45]. Fig-
ure 1 illustrates the main constituent elements. In
Main constituent elements of a surgical interventionFigure 1
Main constituent elements of a surgical intervention.Page 4 of 9
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wider context of the surgical team and pre-operative and
post-operative care are important. Clinically unnecessary
delays in receiving treatment, for example due to waiting
times in a national health service context, can also influ-
ence outcome [47]. A relatively loose definition of the
intervention while maintaining the coherence of the treat-
ment will best reflect practice. A trial comparing hysterec-
tomy versus medical management left the type and route
of the intervention performed at the discretion of the
gynaecologist [38]. In general, broad inclusion criteria
will aid applicability of the results and is to be favoured.
In the Spine Patient Outcome Research Trial, an evalua-
tion of surgical versus non-surgical care for lumbar disc
herniation, only 60% in the surgical arm received surgery
while 45% in the non-surgical arm received surgery, high-
lighting that substantial non-compliance can occur in
some situations [47]. A more explanatory approach with
a tighter definition of participant inclusion and interven-
tion can be warranted. Whatever the focus of the trial,
clear reporting of how the treatment was defined and
compliance is need [48].
Surgical learning curve
A frequent criticism of surgical RCTs, particularly when
evaluating a new innovation against a standard interven-
tion, is that the comparison may be inherently 'unfair' due
to an imbalance in expertise. When a randomised com-
parison of two forms of gastric cancer surgery, contrary to
previous studies, found a higher rate of complications for
the newer D2 surgery, it was argued that the surgeons were
still learning in the trial and the 'true' performance of D2
surgery was not represented [33,49]. This underlying phe-
nomenon of an improvement in performance over time is
commonly referred to as a 'learning curve'. It has been
described as the most intractable of the obstacles to con-
ducting surgical randomised trials [9,50]. Scenarios in
which a surgical learning curve effect could lead to an
incorrect conclusion have been outlined [33].
Two distinct, though related, learning curves can be
defined. First is a community or technology learning
curve, related to refinement of the new intervention (both
technology and technique). Second is the personal learn-
ing of individual surgeons which, though impacted by the
former, is mainly driven by their personal aptitude, train-
ing and surgical experience, although factors such as the
make-up of the surgical team and centre policies also con-
tribute. Training prepares a surgeon for undertaking a sur-
gical intervention; however, the extent to which it can
replace real case experience is unclear, and it would seem
that some expertise can only be acquired in the real-life
setting. By adopting a late evaluation strategy, the first
learning curve will be overcome whereas the latter will
remain, though its impact lessened through the gains of
the former.
Two main options exist for controlling the impact of a
learning curve in the context of a clinical trial: a design
and an analysis approach. In terms of design, entry criteria
for eligible participating surgeons can stipulate character-
istics such as the number of procedures performed, mini-
mum professional level and training received. For
example, a trial comparing open and laparoscopic mesh
repair of inguinal hernias required, prior to participation,
surgeons to have performed 10 laparoscopic interventions
and to demonstrate their competence by undertaking
with supervision another five interventions [51]. Adop-
tion of an expertise-based design for surgical trials would
similarly require some mechanism to identify those with
sufficient 'expertise' to undertake a particular surgical
intervention.
In principle, a statistical assessment of the learning curve
would be preferable as it would allow the impact of the
learning curve on outcome to be quantified. Until recently
this has received relatively little attention, though the
advent of minimally invasive interventions has lead to
increased interest. Ramsay et al reviewed both the assess-
ment of learning curves in health care and also the statis-
tical methods used to assess the learning curve across
disciplines [35]. In general, studies have focussed upon
process measures such as intervention time, blood loss,
hospital stay and complication rates, with little focus
upon more patient-centred outcomes. Generally, the sta-
tistical methods used have been inadequate, though more
sophisticated methods are available which can be used. A
hierarchical model was used for a large trial assessing
suturing material and technique for perineal repair [33]. A
post-hoc analysis in a trial of over 2000 participants,
which compared laparoscopic and open tension-free
mesh repairs of inguinal hernias, found a reduction in
recurrence in the laparoscopic group with surgeon exper-
tise [52]. Due to the large data requirement for analysis,
data on intervention learning is most likely to come, if
available, from large non-randomised studies which can
be incorporated into corresponding economic evalua-
tions. A reduction in the five-year recurrence rate of pros-
tate cancer after radical prostatectomy was observed in a
cohort of over 7000. This reduction persisted, even after a
surgeon had performed a large number of procedures
[53].
Surgical trials should report explicitly and informatively
on the prior expertise of the participating surgeons [54].
Failure to do so will open the trial up to criticism. A survey
of participating surgeons could provide valuable informa-
tion. Justification, with reference to the research question,
should be made for how the existence of a learning curvePage 5 of 9
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expertise levels which are representative of the surgical
community in which the intervention will be used. This
may require a relatively low level of procedural expertise.
A trial conducted by the most experienced surgeons in the
high-caseload centres may not transfer readily to other set-
tings. Conversely, an explanatory trial could seek to
largely exclude learning by only including highly experi-
enced surgeons. An early evaluation could conduct
exploratory statistical analysis of the learning curve [33].
Trial Design issues
Blinding
Blinding – the process of withholding knowledge of the
allocated intervention – is a key consideration when
designing RCTs. Where successfully achieved, it is recog-
nised as playing an important role in preventing the intro-
duction of bias. It can also aid compliance and retention
of participants [55]. Blinding can be applied to partici-
pants, investigators and the outcome assessors of a trial.
Where interventional treatments are involved, blinding
poses a greater challenge than for pharmaceutical-based
treatments [56]. The extent to which blinding is feasible or
necessary will depend upon the nature of the interven-
tions and also the outcome under consideration.
Blinding of the surgeon for evaluations of surgical tech-
niques will be impossible. Outcome assessors can, and
preferably should, be blinded. Surgeons blinded to the
allocation could assess clinical outcomes [57]. A review of
RCTs in a leading orthopaedic journal showed large bias
due to unblinded outcome assessors [58]. However,
blinding is not commonly undertaken in surgical trials
[59]. This is probably partly due to the standard care path-
way, where patients commonly return to the surgeon who
performed their surgery for re-assessment. It may also be
due to the mistaken belief that because the operating sur-
geon cannot be blinded, no blinding is worthwhile or
achievable.
Blinding of participants in surgical trials can often be
achieved. Where two similar surgical interventions are
compared, such as the comparison of two forms of lapar-
oscopic hernia repair, blinding can readily be undertaken.
Where surgical interventions differ significantly, blinding
of the participant is more problematic, though may still
be possible. For example, a trial comparison of laparo-
scopic and open cholecystectomy used the same dressing
for both interventions to allow blinding of participants
and caregivers [60]. Where a surgical intervention is com-
pared with a medical intervention, blinding of the partic-
ipant will not be feasible without some concurrent sham
intervention, which is unlikely to be considered ethical.
The use of placebo or sham surgery, while remaining con-
troversial, has been achieved in a number of cases [61]. A
placebo-controlled evaluation of arthroscopic surgery for
osteoarthritis of the knee found no benefit over the sham
intervention [62]. However, the scope for placebo surgery
is limited to cases where the risk inherent in the placebo
surgery can be balanced against the uncertainty of the
value of the active surgery and its potential harm. Where a
genuine treatment alternative is available, surgical or not,
placebo surgery would seem neither ethical nor desirable.
Mechanism and timing of randomisation
Concealment of future allocation is important. It prevents
manipulation, conscious or not, of group allocation, pro-
tecting the merit of randomisation of balanced groups at
baseline. Where funding permits, an automated tele-
phone randomisation service run by a trial office is prefer-
able. Whatever the mechanism of randomisation, third-
party control is highly desirable. Ideally, treatment will be
received soon after randomisation. Randomisation can be
performed in the operating theatre where participating
surgeons undertake both interventions [51]. Where allo-
cated interventions are performed by different clinicians,
as in an expertise-based trial or medical versus surgical tri-
als, randomisation will need to be earlier. For multicentre
trials stratification is important, as even where the most
technical intervention is involved variation between cen-
tres can be substantial. Minimisation, a numerical
method which allocates a participant to the group which
maximises the equality between groups, can be used to
ensure equally distributed prognostic variables where the
trial size is small by including factors known or believed
to strongly influence treatment outcome [63].
Outcomes
A variety of outcomes are needed in surgical trials: surgical
and clinical outcomes, patient-reported outcomes such as
quality of life measures, and also economic outcomes.
Outcomes related to the surgical process such as compli-
cations and other short-term outcomes have received
much focus, particularly for new and complex interven-
tions. However, longer-term outcomes will for many situ-
ations be more important [9]. Meta-analysts can be
confronted with a plethora of outcomes, with outcomes
such as recurrence or complications having varied defini-
tions. Consensus on which outcomes are important and
how they should be measured is needed. Independent
assessment of outcome is highly desirable. Some out-
comes may be prohibitively rare to base trial sample-size
calculations upon. Data, on which to base sample-size cal-
culations, can be limited. Where substantial uncertainty
exists, an adaptive design approach could be used. In prin-
ciple, all surgical trials will be subject to a clustering effect
and sample sizes should be inflated to account for this,
though the impact is uncertain [64].Page 6 of 9
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Often, surgical details can only feasibly be collected
through self-report by the surgeon. Independent data col-
lection, for example through a study nurse, is preferable.
Adjudication of outcome events by independent and
blinded review of clinical data adds methodological rig-
our. Intra-operative photographic evidence of the proce-
dure has been used to allow independent assessment of
surgical adherence to the protocol [65]. Short-term post-
surgery data is useful for assessing recovery. Collection of
patient-reported outcomes, for example through postal
questionnaires, provides an important perspective [44]. A
meeting of surgeon investigators at the start of a trial along
with site visits/teleconferences during the study can help
clarify and reaffirm the trial protocol and ensure consist-
ent data reporting.
Statistical Analysis
Outcomes following procedures performed by the same
surgeon (or centre) will tend to be more similar than
those performed by another. Statistical methods which
take account of this inherent structure in surgical trials do
exist and should be used in the analysis where studies are
of sufficient size [64]. Subgroups of possible treatment
modifiers should be considered and analysis based upon
a test for an interaction [66]. For a variety of reasons, par-
ticipants randomised to a surgical intervention may not
receive their allocated intervention. Cross-over between
interventions is not uncommon for surgical trials and can
happen prior, during or post the scheduled intervention
and can be asymmetric [47]. RCTs should be analysed by
grouping participants according to their allocated treat-
ment irrespective of subsequent non-compliance. In some
situations an additional analysis, excluding non-compli-
ant cases ('per-protocol' analysis) or using statistical
methods which allow a compliance-based analysis, may
be useful to provide a more realistic estimate of the com-
pliant setting, especially for more explanatory trials [67].
Post-randomisation exclusion may be appropriate where
new clinical information reveals, after randomisation, the
participant not to be suitable for treatment. However,
exclusions threaten the value of randomisation, and rea-
sons should be specified prior to commencement of ran-
domisation [68].
Conclusion
RCTs have played a role in the assessment of surgical
innovations and there is scope and need for greater use.
Surgical trials are difficult to successfully undertake and
pose particular practical and methodological challenges.
However, the inherent value of a well-conducted RCT
should not be overlooked. Collaboration between surgi-
cal and research communities is needed to enable the con-
duct of appropriate and well-designed trials. Three
recommendations for the future conduct of RCTs in sur-
gery are as follows:
• Innovations should be stratified according to their
potential relevance to practice. The highest impact inno-
vations should be prioritised for RCT evaluation where
such an evaluation is ethical and feasible. Surgical com-
munities could take the lead in this process with input
from the research community and funding bodies to
achieve this goal.
• Pragmatic trials have been under-represented in surgery
and this approach should be adopted more widely.
• Exploratory trials (and by extension, tracker trials) can
play a role in the early evaluation of surgical innovations
and should be more readily considered.
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